Scarica l'app Stockscreener
1.20
3.45%
0.04
Dopo l'orario di chiusura:
1.76
0.56
+46.67%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.16
Aprire:
$1.2
Volume 24 ore:
93,454
Relative Volume:
1.21
Capitalizzazione di mercato:
$13.13M
Reddito:
$3,000
Utile/perdita netta:
$-8.23M
Rapporto P/E:
-0.8506
EPS:
-1.4107
Flusso di cassa netto:
$-7.44M
1 W Prestazione:
+1.69%
1M Prestazione:
-11.11%
6M Prestazione:
-11.11%
1 anno Prestazione:
-47.14%
Intervallo 1D:
$1.1401
$1.20
Intervallo di 1 settimana:
$1.11
$1.2299
Portata 52W:
$1.00
$3.20
Biocardia Inc Stock (BCDA) Company Profile
Nome
Biocardia Inc
Settore
Industria
Telefono
650-226-0123
Indirizzo
320 SOQUEL WAY, SUNNYVALE, CA
Compare BCDA vs MOBBW, GOODO, PSNYW, SHMD, DWLD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| 0.41 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
1.90 | 2.52B | 0 | 0 | 0 | 0.00 |
GOODO
Gladstone Commercial Corporation
|
19.70 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
3.94 | 364.47M | 2.07B | -1.42B | -1.37B | -0.6765 |
SHMD
Schmid Group N V
|
5.35 | 297.48M | 52.15M | -21.46M | 0 | -0.4675 |
DWLD
Davis Select Worldwide ETF
|
43.81 | 0 | 0 | 0 | 0 | 0.00 |
Biocardia Inc Stock (BCDA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-04-16 | Downgrade | Dawson James | Buy → Neutral |
Biocardia Inc Borsa (BCDA) Ultime notizie
BioCardia, Inc. (NASDAQ:BCDA) Q4 2025 earnings call transcript - MSN
BioCardia, Inc. (BCDA) stock price, news, quote and history - Yahoo Finance UK
BioCardia submits heart failure trial data to FDA By Investing.com - Investing.com Canada
BioCardia Requests FDA Meeting On Accelerated Approval For CardiAMP In Heart Failure - TradingView
BioCardia Requests FDA Meeting to Discuss Accelerated Approval for CardiAMP Cell Therapy System - geneonline.com
BioCardia submits heart failure trial data to FDA - Investing.com
BioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP® System in Ischemic Heart Failure - The Manila Times
BioCardia Submits CardiAMP HF Study Data to FDA, Plans Meeting for Accelerated Approval Discussion - Quiver Quantitative
Heart failure subgroup saw 47% lower cardiac death as BioCardia heads to FDA - Stock Titan
BioCardia Seeks Accelerated FDA Pathway for CardiAMP HF - tipranks.com
BioCardia files FDA meeting request on accelerated approval for CardiAMP after CardiAMP HF data submission - TradingView
BioCardia (NASDAQ: BCDA) pursues FDA accelerated path for CardiAMP HF - Stock Titan
Revenue per share of BioCardia, Inc. – FWB:6JU0 - TradingView
Book value per share of BioCardia, Inc. – FWB:6JU0 - TradingView
Portfolio Shifts: Can BioCardia Inc expand its profit marginsQuarterly Earnings Summary & Technical Confirmation Trade Alerts - baoquankhu1.vn
Altman Peter, president of BioCardia, buys BCDA stock worth $1.1k - Investing.com Australia
Insider Buying: Peter Altman Acquires Additional Shares of BioCa - GuruFocus
Altman Peter, president of BioCardia, buys BCDA stock worth $1.1k By Investing.com - Investing.com South Africa
BioCardia (BCDA) CEO adds 900 shares in open‑market stock purchases - Stock Titan
Layoff Watch: Is BioCardia Inc in a long term uptrend2026 Trends & Weekly Consistent Profit Watchlists - baoquankhu1.vn
BioCardia, Inc. (NASDAQ:BCDA) Q4 2025 Earnings Call Transcript - insidermonkey.com
BioCardia, Inc. Q4 2025 Earnings Call Summary - finance.yahoo.com
BioCardia (BCDA) Projected to Post Quarterly Earnings on Wednesday - Defense World
BioCardia outlines imminent CardiAMP FDA submission and targets regulatory catalysts as trial data signals clinical benefit - MSN
BioCardia, Inc. Reports 2026 Financial Results and CardiAMP Clinical Program Updates - Minichart
BioCardia Inc (BCDA) Q4 2025 Earnings Call Highlights: Promising Clinical Results Amid ... By GuruFocus - ca.investing.com
BioCardia Inc (BCDA) Q4 2025 Earnings Call Highlights: Promising Clinical Results Amid Financial Challenges - GuruFocus
BioCardia (BCDA) Highlights Clinical Progress and Financials in Q4 2025 - GuruFocus
BioCardia, Inc.: Advancing Cell Therapy Systems for Heart Failure and Cardiovascular Disease – Clinical Trials, FDA Approvals, and Business Strategies (2025) - Minichart
Earnings Call Summary | BioCardia(BCDA.US) Q4 2025 Earnings Conference - 富途牛牛
BioCardia, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:BCDA) 2026-03-24 - Seeking Alpha
Biocardia Inc's HF2 Trial Enrollment and Regulatory Timeline Claims Clash in 2025 Earnings Calls - Bitget
Earnings call transcript: Biocardia’s Q4 2025 results show focus on clinical progress By Investing.com - Investing.com South Africa
BCDA: Phase III CardiAMP HF data support regulatory filings as financials remain stable and catalysts approach - TradingView
Earnings call transcript: Biocardia’s Q4 2025 results show focus on clinical progress - Investing.com Canada
BioCardia Inc reports results for the quarter ended December 31Earnings Summary - tradingview.com
BCDA: CardiAMP therapy advances toward regulatory approval with strong clinical data and stable finances - TradingView
BIOCARDIA ($BCDA) Releases Q4 2025 Earnings - Quiver Quantitative
BCDA: Positive clinical trial results and regulatory progress, but net loss widened to $8.2 million - TradingView
Q4 2025 BioCardia Inc Earnings Call Transcript - gurufocus.com
[10-K] BioCardia, Inc. Files Annua... - Stock Titan
BioCardia Reports 2025 Business Highlights and Financial Results - The Manila Times
BioCardia (BCDA) Likely to Undergo Significant Dilution Soon Ahead of Major Phase 3 Results - Bitget
BioCardia, Inc. Auditor Raises 'Going Concern' Doubt - MarketScreener
BioCardia Inc expected to post a loss of 17 cents a shareEarnings Preview - TradingView
BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026 - The Manila Times
BioCardia, Inc. to Host Conference Call for 2025 Financial Results and Corporate Update on March 24, 2026 - Quiver Quantitative
BioCardia to give corporate update with 2025 results on March 24 - Stock Titan
Quarterly Risk: Does BioCardia Inc stock have upside surprise potential2026 Technical Overview & Expert Approved Trade Ideas - baoquankhu1.vn
FDA accepts BioCardia pre-submission for Helix catheter By Investing.com - za.investing.com
BioCardia Inc Announces Pre-Submission Approval Package for Helix Transendocardial Delivery Catheter Accepted by FDA - marketscreener.com
Biocardia Inc Azioni (BCDA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):